Open Orphan PLC Appointment of Nominated Adviser and Joint Broker (5920J)
April 28 2022 - 2:02AM
UK Regulatory
TIDMORPH
RNS Number : 5920J
Open Orphan PLC
28 April 2022
Open Orphan plc
("Open Orphan" or the "Company")
Appointment of Nominated Adviser and Joint Broker
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge
clinical trials, announces that further to the announcements by
Arden Partners Plc on 11 and 14 April 2022 regarding the loss of
its Nominated Adviser status upon the completion of its recommended
takeover, the Company has appointed Liberum Capital Limited
("Liberum") as its Nominated Adviser and Joint Broker. Given the
timing of the completion of the recommended takeover of Arden
Partners Plc, the Exchange has agreed that subject to initial due
diligence being undertaken, Liberum has until 5pm on 27 July 2022
to complete its full due diligence.
There can be no guarantee on the outcome of the full due
diligence and its impact on Liberum's decision to continue to act
as Nominated Adviser. Accordingly, in such circumstances there is a
risk that if the Liberum does not continue to act as Nominated
Adviser following completion of its full due diligence and the
Company has not found an alternative Nominated Adviser, the
Company's AIM securities may be suspended pursuant to AIM Rule 1.
If within one month of that suspension, the Company has failed to
appoint a replacement Nominated Adviser, the admission of its AIM
securities will be cancelled.
Notwithstanding the extension of time provided in respect of
completing full due diligence obligations at engagement, Liberum
will continue to be subject to all the ongoing Nominated Adviser
responsibilities under the AIM Rules for Nominated Advisers.
finnCap plc and Davy will continue to act as the Company's Joint
Brokers.
Yamin 'Mo' Khan, Chief Executive Officer at Open Orphan, said: "
As the market is aware, Arden Partners can no longer act as Nomad
for listed companies from 29 April 2022 and as such, we thank them
for their support over the past number of years. We are delighted
to now be working with such a prestigious investment bank as
Liberum."
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Yamin Khan, Chief Executive Officer
Liberum Capital (Nominated Adviser
and Joint Broker) +44 (0) 20 3100 2000
Ben Cryer/ Edward Mansfield/ Phil
Walker/ Will King
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson / Richard
Chambers
Davy (Euronext Growth Adviser and
Joint Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Paul McManus / Sam Allen / Louis +44 (0)7980 541 893 / +44 (0) 7502 558
Ashe-Jepson 258 / +44 (0)
7747 515393
Notes to Editors
Open Orphan plc
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
contract research company that is a world leader in testing
infectious and respiratory disease products using human challenge
clinical trials. The Company provides services to Big Pharma,
biotech, and government/public health organisations.
The Company has a leading portfolio of human challenge study
models for infectious and respiratory diseases, including the
recently established COVID-19 model, and is developing a number of
new models, such as Malaria, to address the dramatic growth of the
global infectious disease market. The Paris and Breda offices have
over 25 years of experience providing drug development services
such as biometry, data management, statistics CMC, PK and medical
writing to third party clients as well as supporting the
London-based challenge studies.
Open Orphan runs challenge studies in London from its
Whitechapel quarantine clinic, its state-of-the-art QMB clinic with
its highly specialised on-site virology and immunology laboratory,
and its newly opened clinic in Plumbers Row. To recruit volunteers
/ patients for its studies, the Company leverages its unique
clinical trial recruitment capacity via its FluCamp volunteer
screening facilities in London and Manchester. The newly opened
facilities have expanded the scope of the business to enable the
offering of Phase I and Phase II vaccine field trials, PK studies,
bridging studies, and patient trials as part of large international
multi-centre studies.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological, and digital (wearable) biomarkers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPFLFEESVIDFIF
(END) Dow Jones Newswires
April 28, 2022 02:02 ET (06:02 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024